IRVINE, Calif., Aug. 08, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Mazor Robotics Ltd. (“Mazor Robotics” or the “Company”) (Nasdaq:MZOR). Investors who purchased or otherwise acquired shares from November 8, 2016 through June 8, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by August 8, 2017, the lead plaintiff motion deadline.
If you purchased shares of Mazor Robotics during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
The Complaint alleges that throughout the Class Period, Mazor Robotics made false and misleading statements and/or failed to disclose: that the Company engaged in conduct that subjected it to an Israeli Securities Authority (“ISA”) investigation and exposed it to potential liability; and that as a result, the Company’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. On June 8, 2017, Mazor Robotics revealed that in May 2017, the ISA searched its offices and questioned certain of its officers regarding an investigation. Following this news, the Company’s stock price fell materially, which harmed investors according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 



